Sabiia Seb
PortuguêsEspañolEnglish
Embrapa
        Busca avançada

Botão Atualizar


Botão Atualizar

Registro completo
Provedor de dados:  BJID
País:  Brazil
Título:  Molecular diagnosis of symptomatic toxoplasmosis: a 9-year retrospective and prospective study in a referral laboratory in São Paulo, Brazil
Autores:  Camilo,Lilian Muniz
Pereira-Chioccola,Vera Lucia
Gava,Ricardo
Meira-Strejevitch,Cristina da Silva
Vidal,Jose Ernesto
Mattos,Cinara Cássia Brandão de
Frederico,Fábio Batista
De Mattos,Luiz Carlos
Spegiorin,Lígia Cosentino Junqueira Franco
Murata,Fernando Henrique Antunes
Ferreira,Marina Neves
Barbosa,Deusenia Machado Ulisses
Gonçalves,Fausto da Silva
Dias,Cristiane Moraes
Catelan,Marcia Wakai
Siqueira,Rubens Camargo
Previato,Mariana
Barbosa,Amanda Pires
Cavallini,Danilo
Data:  2017-12-01
Ano:  2017
Palavras-chave:  Toxoplasma gondii
Symptomatic toxoplasmosis
Diagnosis
Real-time polymerase chain reaction
Resumo:  ABSTRACT Symptomatic forms of toxoplasmosis are a serious public health problem and occur in around 10-20% of the infected people. Aiming to improve the molecular diagnosis of symptomatic toxoplasmosis in Brazilian patients, this study evaluated the performance of real time PCR testing two primer sets (B1 and REP-529) in detecting Toxoplasma gondii DNA. The methodology was assayed in 807 clinical samples with known clinical diagnosis, ELISA, and conventional PCR results in a 9-year period. All samples were from patients with clinical suspicion of several features of toxoplasmosis. According to the minimum detection limit curve (in CT), REP-529 had greater sensitivity to detect T. gondii DNA than B1. Both primer sets were retrospectively evaluated using 515 DNA from different clinical samples. The 122 patients without toxoplasmosis provided high specificity (REP-529, 99.2% and B1, 100%). From the 393 samples with positive ELISA, 146 had clinical diagnosis of toxoplasmosis and positive conventional PCR. REP-529 and B1 sensitivities were 95.9% and 83.6%, respectively. Comparison of REP-529 and B1 performances was further analyzed prospectively in 292 samples. Thus, from a total of 807 DNA analyzed, 217 (26.89%) had positive PCR with, at least one primer set and symptomatic toxoplasmosis confirmed by clinical diagnosis. REP-529 was positive in 97.23%, whereas B1 amplified only 78.80%. After comparing several samples in a Brazilian referral laboratory, this study concluded that REP-529 primer set had better performance than B1 one. These observations were based after using cases with defined clinical diagnosis, ELISA, and conventional PCR.
Tipo:  Info:eu-repo/semantics/article
Idioma:  Inglês
Identificador:  http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1413-86702017000600638
Editor:  Brazilian Society of Infectious Diseases
Relação:  10.1016/j.bjid.2017.07.003
Formato:  text/html
Fonte:  Brazilian Journal of Infectious Diseases v.21 n.6 2017
Direitos:  info:eu-repo/semantics/openAccess
Fechar
 

Empresa Brasileira de Pesquisa Agropecuária - Embrapa
Todos os direitos reservados, conforme Lei n° 9.610
Política de Privacidade
Área restrita

Embrapa
Parque Estação Biológica - PqEB s/n°
Brasília, DF - Brasil - CEP 70770-901
Fone: (61) 3448-4433 - Fax: (61) 3448-4890 / 3448-4891 SAC: https://www.embrapa.br/fale-conosco

Valid HTML 4.01 Transitional